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Abstract
Alkaptonuria (ochronosis) is a rare autosomal recessive disorder featuring a genetic error in the amino acid metabolism. A defect in the
tyrosine metabolism results in the accumulation and deposition of homogentisic acid in connective tissue, causing a blue-black discoloura-
tion. Degenerative arthropathy of the spine, knee, and hip are common signs of ochronosis in older age. An association between ochrono-
sis and depression has not previously been discussed in the literature. This case report describes a 69 year-old woman with diabetes
mellitus, ochronosis, depression and chronic pain. (Pol J Endocrinol 2010; 61 (6): 710–713)
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Streszczenie
Alkaptoniuria (ochronoza) jest rzadką, dziedziczoną w sposób autosomalny recesywny chorobą metaboliczną, która polega na genety-
cznym defekcie przemiany aminokwasu, tyrozyny. Defekt ten powoduje gromadzenie się i odkładanie kwasu homogentyzynowego
w tkance łącznej powodujące jej niebiesko-czarne zabarwienie. Częstymi objawami ochronozy w starszym wieku są zmiany zwyrodnie-
niowe stawów kręgosłupa, kolan i bioder. W bibliografii nie znaleziono opracowań dotyczących związku między ochronozą i depresją.
Niniejszy opis przedstawia przypadek 69-letniej kobiety cierpiącej z powodu ochronozy, depresji i przewlekłego bólu.
(Endokrynol Pol 2010; 61 (6): 710–713)
Słowa kluczowe: alkaptonuria, przewlekły ból, depresja, wiek starszy, ochronoza, cukrzyca
Introduction
Ochronosis, often called alkaptonuric ochronosis, is a rare
autosomal recessive metabolic disorder. It causes the ac-
cumulation and deposition of homogentisic acid oxidase
(HGA), resulting in bluish black discolouration, calcifica-
tion, chronic inflammation and degeneration of cartilag-
inous and related tissues throughout the body [1].
Depressive illness in older people is a serious and
common health problem leading to unnecessary suf-
fering, impaired functional status, increased mortality
and morbidity, and excessive use of health care systems.
Diagnosing depression in the elderly can be difficult
because its symptoms overlap with those of other chron-
ic illnesses, leading it to be frequently overlooked [2, 3].
Since depression is both treatable and associated with
increased mortality, it seems reasonable to make every
attempt to diagnose patients.
Until now, the association between depression and
ochronosis has not been discussed in the literature. This
report presents the case of an elderly patient with ochro-
nosis also suffering from depression and chronic pain.
Case report
A 69 year-old woman with an eight year history of
ochronosis was referred to the clinic in May 2009, be-
cause of forgetfulness and chronic pain. She had expe-
rienced pain in all parts of her body for the previous
two years and was taking analgesic/anti-inflammatory
and myorelaxant drugs almost every day. She had de-
rived benefit from these drugs, but nevertheless, she
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complained of appetite loss, fatigue, a feeling of hope-
lessness, sleeping difficulties, and an inability to enjoy
life over the past year. Also, she had lost eight kilograms
during this time.
Her family history showed two siblings who had
been diagnosed with ochronosis. A review of her med-
ical history revealed diabetes mellitus, hypertension,
coronary artery disease, and ochronotic arthritis. Her
surgical history was significant for cholesystectomy. Her
present medications were metformine, amlodipine, val-
sartan, isosorbid-5-mononitrate, acetylsalicylic acid, and
diclofenac sodium for pain. She had no known drug
allergies and denied smoking or alcohol use. The sub-
ject was given an information sheet, and written in-
formed consent was obtained from her.
On admission, physical examination revealed an
older woman with depressive mood and severe pain
secondary to neck and back, and bilateral knee pain.
The patient’s height was 153 cm, and weight 68 kg.
Vital signs were as follows: arterial blood pressure,
140/90 mm Hg; pulse rate, 78 beats/min (regular and
rhythmic); respiratory rate, 18 breaths per minute; room
air oxygen saturation, 96%; oral temperature, 36.5°C.
She had a blue-black pigmentation on her sclera, the
tip of her nose, ears, face, hands, feet, and, significant-
ly, in palmo-plantar regions the palms of her hands and
the soles of her feet (Fig. 1). Auscultation revealed that
her lung sounds were clear bilaterally. On cardiac ex-
amination, the first heart sound was loud and there was
a mid-systolic murmur (2/6) on apex and second inter-
costal space. Abdominal examination was normal. There
was restricted range of motion in neck, knees, and lum-
bar spine. In addition, the coarse crepitus was associat-
ed with chronic systemic arthralgias and pain. Urine
color was normal, but turned dark after 15 minutes. Her
cognitive function remained intact and there was no
evidence of a psychotic disorder. Her score on visual
analog scale (VAS) was 9 (range 0–10) [4].
Laboratory data showed a normochrom-normocyt-
ic anaemia (hematocrit, 32.2%; haemoglobin concentra-
tion 10.9 g/dL). Other values revealed were: sedimen-
tation rate 35 mm/h; serum glucose concentration —
105 mg/dL, HbA1c levels — 6.4%, serum urea nitrogen
concentration — 23 mg/dL, creatinine level — 0.9 mg/
/dL; uric acid — 2.9 mg/dl; sodium — 137.2 mmol/L;
potassium — 4.55 mmol/L; calcium — 9.28 mg/dL; phos-
phorus — 3.48 mg/dL, total cholesterol — 197 mg/dL;
triglyceride — 106 mg/dL; LDL-cholesterol — 139 mg/
/dL, HDL-cholesterol — 41 mg/dL; and albumin —
4.3 g/dL. Also, thyroid function tests were normal. An-
tero-posterior radiographies of cervical and lumbosac-
ral vertebrae and knees showed the characteristic fea-
tures of late stage ochronosis.
Medical evaluation of her weight loss did not reveal
a malignancy or malabsorption. Physical therapy was
started for her neck, lower back, and knee pain. After
ten sessions, her complaints had not resolved and so
tramadole (50 mg/day) was added to the regime. In the
control visit one month later, she stated that her pain
was a little decreased, but not relieved (VAS 8/10). She
was consulted by an experienced psychiatrist about her
history of depressive complaints which were thought
to be secondary to her pain. The patient completed
a Yesavage Geriatric Depression Scale at the same visit.
Her score on the scale was 12 (range 0–15, with scores
greater than 11 indicative of depression) [5]. She was
diagnosed as suffering from a major depressive disor-
der based on Diagnostic and Statistical Manual of Men-
tal Disorders, fourth edition, text revision (DSM-IV-TR)
[6]. Thus, mirtazapine (15 mg/day) was started for de-
pression and sleep disturbance. Effects of the treatment
on pain and depressive complaints were observed in
the control visit after one month (Yesavage score 8/15
and VAS 5/10). One month later, she was feeling less
fatigued. Appetite loss, sleep disturbance and mobility
had improved. However, she continued to feel hope-
less and did not engage in her previous activities. To
obtain an optimal result, the dosages of mirtazapine and
tramadole were increased to 30 mg and 100 mg, respec-
tively. In the control visit at the third month, her general
complaints and pain had reduced, and depressive
Figure 1.
Rycina 1.
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symptoms were significantly improved (Yesavage score
3/15 and VAS 3/10). The patient reported that she felt
“less depressed”, and attributed this to her antidepres-
sant medication and pain-relief drug (Table I). She was
followed-up in our clinic uneventfully.
Discussion
To the best of our knowledge, this is the first case de-
scribing combined depression and ochronosis in the lit-
erature. Management of this complex patient required
simultaneous consideration of depression, sleep distur-
bance, and chronic pain due to ochronotic arthropathy.
This case report has a number of interesting find-
ings that warrant further exploration and discussion.
First, the patient’s depressive symptoms were closely
related to her pain from the ochronotic arthritis. Sec-
ondly, the combination of antidepressants and trama-
dole lifted the patient’s depression and physical symp-
toms. Lastly, no reports on depression in ochronotic
older patients have been published; our findings indi-
cate that mirtazapine and tramadole may exert addi-
tional effects on ochronotic older patients.
First described in 1866, ochronosis is the accumula-
tion of a pigment in the skin, cartilage, and collagenous
tissues of the whole body. The genetic defect is mapped
to the HGO gene on arm 3q1 and 18 genetic missense
mutations are found to cause HGA oxidase aberrations
[7]. The major clinical manifestations of this disorder are
related to deposition of a pigment within the affected or-
gans. Thus, a patient with ochronosis has pigmented skin
and often has severe arthritis and pain, restrictive lung
dysfunction, degenerative cardiovascular disease, and re-
nal and prostatic calculi. At the present state of knowl-
edge, no curable medical therapy is available for ochrono-
sis and treatment is only based on symptomatology [1].
Depression can cause severe functional disability
and even serious suicide attempts in the elderly. How-
ever, making a diagnosis of depression in the elderly
can often be difficult in general practice. The idea that
experiencing depressive symptoms is a ‘normal’ part of
ageing, or that they are related to a physical disorder,
cause a delay in diagnosis. There are many studies in-
vestigating the relationship between depression and
physical disease. It has been shown that angina, diabe-
tes, chronic bronchitis, arthritis, visual impairments,
heart attacks and other cardiac diseases, rheumatism,
lung diseases, cancer, and vascular events increase the
risk of depression in older people [8–10]. Some of these
diseases may bring about functional restrictions. So,
physical problems may lead to depression by causing
social isolation. Those elderly  people with movement
restrictions are especially at risk in this respect [8].
Osteoarthritis is the commonest type of arthritis in
older people. Arthritis-related pain and depression are
complex problems negatively affecting quality of life
and physical functions [11]. Studies in the community
have found elevated risks of depression among older
people with chronic pain. The relationship between pain
and depression is still poorly understood [11]. Depres-
sion and arthritis may be further linked through com-
mon inflammatory pathways, in which cytokines seem
to play a major role [12]. In the case of the elderly with
ochronosis, however, an association between disturbed
tyrosine metabolism and depression having never been
discussed in the literature, we speculate that activation
of inflammatory pathways by HGA may cause a link
between depression and ochronotic arthritis, or may be
part of the explanation for this connection. Cytokines
that are released in response to an activation of inflam-
matory pathways by HGA can enter the brain and then
they may cause alterations of the metabolism of seroto-
Table I. Clinical course of the patient
Tabela I. Przebieg choroby u pacjentki
Date Symptom VAS YGDS Started therapy
Admission (Day 0) Pain, forgetfulness, appetite loss, fatigue, 9
hopelessness, inability to enjoy life,
sleeping difficulties
Day 3 Same complaints 9 Physical therapy (ten sessions)
Day 17 Same complaints 9 TMD (50 mg/day)
Day 30 Pain was a little decreased and other symptoms 8 12 TMD (50 mg/day) + MTZ (15 mg/day)
continued
Day 60 Decreased pain, forgetfulness, hopelessness, 5 8 TMD (100 mg/day) + MTZ (30 mg/day)
and inability to enjoy life
Day 90 Hopelessness and inability to enjoy life 3 3 TMD (100 mg/day) + MTZ (30 mg/day)
VAS — Visual analog scale (range 0–10); YGDS — Yesavage Geriatric Depression Scale (range 0–15); TMD — tramadole; MTZ — mirtazapine
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nin and dopamine [13]. Future studies are required to
explore the underlying mechanisms.
Until now, most studies have examined whether an-
tidepressant treatments have a helpful effect on pain
conditions. Unfortunately, no report has been found in
the literature as to whether pain-relieving medications
improve depressive symptoms. It has been reported that
pain-relieving medications have little intrinsic antidepres-
sant effect [14]. More research is needed to determine if
alleviation of pain helps patients’ depressive symptoms.
At the first application of the case to our clinic, it
was thought that the patient’s pains were related to
ochronosis. The desired response could not be obtained
despite the arrangement of treatment. Furthermore, the
depressive symptoms described in the history were con-
sidered as secondary to the physical complaints. But,
the response to the arranged treatment was not as good
as expected and the depressive symptoms continued
as before. Then, the patient was questioned for more
details, and a decision was made for psychiatric con-
sultation. In this consultation, the psychiatrist added an
antidepressant (mirtazapine 15 mg/day) to the treat-
ment regime. The patient was examined again after four
weeks and it was decided to increase the dosages of mir-
tazapine (to 30 mg/day) and tramadole (to 100 mg/day).
In this case, we found that antidepressant treatment
was as effective as the increased tramadole dosage on
the marked reduction of pain. This pleiotropic effect of
mirtazapine may develop by itself, or by increasing the
activity of tramadole on neurons. In line with this, some
biological evidence suggests that dysfunctional seroton-
ergic and noradrenergic neurons could affect ascend-
ing and descending pathways, causing symptoms of
depression and pain [15, 16].
Conclusions
It is important to bear in mind that prolonged and un-
treated pain in the elderly with ochronosis may cause
depression. Depressive symptoms in ochronotic pa-
tients must not be overlooked by considering them as
a normal part of the disease or of old age. Considering
both of these factors, screening for depression in the
elderly population seems prudent. Identifying depres-
sion is important because these patients may be at risk of
increased morbidity and mortality, although comprehen-
sive data regarding outcomes is lacking. Future research
is needed to test whether a care management approach
integrating both ochronotic arthritis and depression treat-
ments can produce additional health gains for older peo-
ple with ochronotic arthritis and depression.
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